Rob Carlson
Founder @ Biodesic
Frederick, United States
Rob Carlson is a Series A investor at Biodesic in Frederick focused on Biotechnology and Genetics. Rob is interested in the future role of biology as a human technology and is a founder of Biodesic, a consulting firm at the juncture of biology and other disciplines such as marketing, engineering, and investment. He has worked to develop new biological technologies in both academic and commercial environments, focusing on molecular measurementand microfluidic systems. Carlson is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Rob Carlson invests in
Stages Rob Carlson invests in
Countries Rob Carlson invests in
Investment Focus
Industry
- Biotechnology 2 (67%)
- Genetics 1 (33%)
- Life Science 1 (33%)
- Bioinformatics 1 (33%)
- Environmental Consulting 1 (33%)
Stage
- Series A 2 (67%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ZymeCO
|
ZymeCO is a bio-manufacturing company that develops enzyme-based biological products designed for sustainable agriculture and turf management. The company utilizes a bio-process that transforms organic matter to build soil health, accelerate residue decomposition, and boost plant growth. | $4M / Series A / Jul 01, 2026 | |
Parse Biosciences
|
Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $41.5M / Series B / Feb 15, 2022 | |
|
Parse Biosciences
|
Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers.By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enablessamples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020.The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig. | $7M / Series A / Jan 26, 2021 |
Co-Investors
Ag Startup Engine
1 deal together
Janus Henderson Investors
1 deal together
Logos Capital
1 deal together
Marshall Wace
1 deal together
Old Tom Capital
1 deal together
Sahsen Ventures
1 deal together
About Biodesic
Biodesic Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Rob Carlson
Founder
|
|||
|
Rik Wehbring
Principal
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rob Carlson invest in?
Rob Carlson invests primarily in Biotechnology, Genetics and Life Science startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Rob Carlson last invest?
The most recent investment recorded for Rob Carlson closed in Jul 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
